BR112017017303B8 - Método para obtenção de clones de células de alta produtividade - Google Patents
Método para obtenção de clones de células de alta produtividadeInfo
- Publication number
- BR112017017303B8 BR112017017303B8 BR112017017303A BR112017017303A BR112017017303B8 BR 112017017303 B8 BR112017017303 B8 BR 112017017303B8 BR 112017017303 A BR112017017303 A BR 112017017303A BR 112017017303 A BR112017017303 A BR 112017017303A BR 112017017303 B8 BR112017017303 B8 BR 112017017303B8
- Authority
- BR
- Brazil
- Prior art keywords
- cell clones
- protein
- obtaining high
- cells
- recombinant antibody
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000001963 growth medium Substances 0.000 abstract 3
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 2
- 230000006978 adaptation Effects 0.000 abstract 2
- 238000012258 culturing Methods 0.000 abstract 2
- 238000000855 fermentation Methods 0.000 abstract 2
- 230000004151 fermentation Effects 0.000 abstract 2
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 2
- 238000009776 industrial production Methods 0.000 abstract 1
- 239000002609 medium Substances 0.000 abstract 1
- 230000010412 perfusion Effects 0.000 abstract 1
- 230000010473 stable expression Effects 0.000 abstract 1
- 230000003068 static effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
método para obtenção de clones de células de alta produtividade, linhagem de células de mieloma, e, anticorpo recombinante humanizado. é fornecido um método para a obtenção de clones de células de expressão estável de alto rendimento a partir de linhagens de células de mieloma em um meio de cultura isento de proteína. o método é usado para a produção industrial de um anticorpo recombinante e inclui três estágios: (1) adaptação a um meio de cultura isento de proteína, cultura estática de células em uma baixa densidade e redução gradual de um suplemento rico em gordura para um meio de cultura químico; (2) adaptação a um meio de cultura isento de proteína; cultura de células em uma alta densidade e uso de um sistema de fermentação por perfusão em escala laboratorial; e (3) rastreamento de clones de células de expressão estável de alto rendimento das células após a fermentação terminar. o clone celular pode ser usado para produzir um anticorpo recombinante anti-neugcgm3 14f7 humanizado.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510080631.3 | 2015-02-14 | ||
| CN201510080631.3A CN104651314B (zh) | 2015-02-14 | 2015-02-14 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
| PCT/CN2016/076135 WO2016127954A1 (zh) | 2015-02-14 | 2016-03-11 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112017017303A2 BR112017017303A2 (pt) | 2018-04-10 |
| BR112017017303B1 BR112017017303B1 (pt) | 2023-08-08 |
| BR112017017303B8 true BR112017017303B8 (pt) | 2024-03-05 |
Family
ID=53242962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017017303A BR112017017303B8 (pt) | 2015-02-14 | 2016-03-11 | Método para obtenção de clones de células de alta produtividade |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10457747B2 (pt) |
| JP (1) | JP2018506306A (pt) |
| KR (1) | KR20180029948A (pt) |
| CN (1) | CN104651314B (pt) |
| AU (1) | AU2016218641C1 (pt) |
| BR (1) | BR112017017303B8 (pt) |
| CA (1) | CA2974027C (pt) |
| CO (1) | CO2017008087A2 (pt) |
| CU (1) | CU20170106A7 (pt) |
| EA (1) | EA201791828A1 (pt) |
| IL (1) | IL253932A0 (pt) |
| MX (1) | MX2017010421A (pt) |
| MY (1) | MY192147A (pt) |
| NZ (1) | NZ735485A (pt) |
| SG (1) | SG11201706595TA (pt) |
| TN (1) | TN2017000302A1 (pt) |
| WO (1) | WO2016127954A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104651314B (zh) * | 2015-02-14 | 2018-06-19 | 百泰生物药业有限公司 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
| EP3257935A4 (en) * | 2016-03-11 | 2018-08-08 | Biotech Pharmaceutical Co. Ltd. | Method for obtaining high-yield, stable-expression cell clones and antibody molecules obtained thereby |
| CN113480652B (zh) * | 2021-07-30 | 2023-04-07 | 成都景泽生物制药有限公司 | 一种重组cho细胞发酵培养生产重组egfr抗体活性分子的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22731A1 (es) * | 1998-02-05 | 2002-02-28 | Centro Inmunologia Molecular | Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen |
| GB0208041D0 (en) * | 2002-04-08 | 2002-05-22 | Lonza Biologics Plc | Method of culturing animal cells |
| CU23097A1 (es) * | 2002-10-23 | 2005-11-18 | Centro Inmunologia Molecular | Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método |
| CU23403A1 (es) * | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| JP2007510416A (ja) * | 2003-11-03 | 2007-04-26 | セントカー・インコーポレーテツド | バイオプロセッシングシステムにおいて低剪断を維持する方法 |
| CU24120B1 (es) * | 2012-03-01 | 2015-08-27 | Ct De Inmunología Molecular | Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3 |
| CN104152415B (zh) * | 2014-08-13 | 2015-09-30 | 百泰生物药业有限公司 | 获得高产稳定表达重组抗体的骨髓瘤细胞株的方法及应用 |
| CN104651314B (zh) * | 2015-02-14 | 2018-06-19 | 百泰生物药业有限公司 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
-
2015
- 2015-02-14 CN CN201510080631.3A patent/CN104651314B/zh active Active
-
2016
- 2016-03-11 CA CA2974027A patent/CA2974027C/en active Active
- 2016-03-11 BR BR112017017303A patent/BR112017017303B8/pt active IP Right Grant
- 2016-03-11 NZ NZ735485A patent/NZ735485A/en active IP Right Revival
- 2016-03-11 TN TNP/2017/000302A patent/TN2017000302A1/en unknown
- 2016-03-11 EA EA201791828A patent/EA201791828A1/ru unknown
- 2016-03-11 KR KR1020177022618A patent/KR20180029948A/ko not_active Application Discontinuation
- 2016-03-11 CU CUP2017000106A patent/CU20170106A7/xx unknown
- 2016-03-11 MY MYPI2017702967A patent/MY192147A/en unknown
- 2016-03-11 JP JP2017560865A patent/JP2018506306A/ja active Pending
- 2016-03-11 AU AU2016218641A patent/AU2016218641C1/en active Active
- 2016-03-11 US US15/549,087 patent/US10457747B2/en active Active
- 2016-03-11 SG SG11201706595TA patent/SG11201706595TA/en unknown
- 2016-03-11 WO PCT/CN2016/076135 patent/WO2016127954A1/zh active Application Filing
- 2016-03-11 MX MX2017010421A patent/MX2017010421A/es unknown
-
2017
- 2017-08-09 IL IL253932A patent/IL253932A0/en unknown
- 2017-08-10 CO CONC2017/0008087A patent/CO2017008087A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201706595TA (en) | 2017-09-28 |
| BR112017017303B1 (pt) | 2023-08-08 |
| EA201791828A1 (ru) | 2017-12-29 |
| KR20180029948A (ko) | 2018-03-21 |
| IL253932A0 (en) | 2017-10-31 |
| CN104651314A (zh) | 2015-05-27 |
| NZ735485A (en) | 2019-08-30 |
| CU20170106A7 (es) | 2018-06-05 |
| AU2016218641A1 (en) | 2017-10-05 |
| CA2974027C (en) | 2021-02-16 |
| CA2974027A1 (en) | 2016-08-18 |
| US10457747B2 (en) | 2019-10-29 |
| TN2017000302A1 (en) | 2019-01-16 |
| CN104651314B (zh) | 2018-06-19 |
| CO2017008087A2 (es) | 2017-10-10 |
| BR112017017303A2 (pt) | 2018-04-10 |
| AU2016218641B2 (en) | 2019-10-31 |
| US20180016353A1 (en) | 2018-01-18 |
| WO2016127954A1 (zh) | 2016-08-18 |
| JP2018506306A (ja) | 2018-03-08 |
| MY192147A (en) | 2022-08-01 |
| AU2016218641C1 (en) | 2020-02-27 |
| MX2017010421A (es) | 2018-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018003214A2 (pt) | fabricação de fosfatases alcalinas | |
| BR112018002214A2 (pt) | ?métodos para cultivar células e para produzir uma proteína, meios de cultura de células cho e de batelada alimentada e/ou alimentação, e, alimentação de cultura de células cho? | |
| BR112015019950A2 (pt) | Método para gerar linhagem de células-tronco embrionárias (es) de rato, e, cultura in vitro | |
| BR112018008648A2 (pt) | métodos de geração de células t a partir de células tronco e métodos imunoterapêuticos ao usar células t | |
| NZ597742A (en) | Method of producing a polypeptide or virus of interest in a continuous cell culture | |
| EA201991976A1 (ru) | Метаболически оптимизированная клеточная культура | |
| EP3546570A4 (en) | KIT WITH MEDIUM FOR THE CULTURE OF SERUM-FREE IMMUNELL CELLS, METHOD FOR THE CULTURE OF IMMUNAL CELLS BY USE OF THE KIT, SERUM-FREE IMMUNE CELL CULTURE RECEIVED BY THE KIT OR CULTURE METHOD AND COSMETIC COMPOSITION | |
| SG11201808590TA (en) | Fibroin-like protein variant and cell culture method | |
| BR112018011902A2 (pt) | método de fermentação, levedura geneticamente modificada, construto de ácido nucleico, vetor, célula hospedeira, meio de fermentação e utilização da levedura geneticamente modificada | |
| BRPI0811177A2 (pt) | Titulações de polipeptídeo do fator viii em culturas de células | |
| EA201171018A1 (ru) | Биореактор для культивирования клеток млекопитающих | |
| EA201290797A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ АДЕНОВИРУСНЫХ ВЕКТОРОВ Ad26 | |
| SG10201810830UA (en) | Cell culture compositions and methods for polypeptide production | |
| EA202091407A1 (ru) | Состав бессывороточной среды для культивирования клеток и способы его применения | |
| BR112013020217A2 (pt) | método e biorreator para o cultivo de micro-organismos | |
| MX2021007613A (es) | Metodos de establecimiento de bancos de celulas de densidad ultra-alta. | |
| EA202091422A1 (ru) | Способ непрерывного производства продуктов на основе биспецифических антител | |
| BR112017017303B8 (pt) | Método para obtenção de clones de células de alta produtividade | |
| EA201492185A1 (ru) | Способ получения рекомбинантной идуронат-2-сульфатазы | |
| BR112016028512A8 (pt) | método de cultivo de uma célula de mamífero e método de produção de uma proteína recombinante | |
| BR112018007590A2 (pt) | método para produzir proteína de fusão que tem domínio fc de igg | |
| EP3569688A4 (en) | CELL CULTURE SUBSTRATE, CULTURE CONTAINER, PROCESS FOR PRODUCING A CELL CULTURE CONTAINER, PROCESS FOR OBTAINING CELLS AND PROCESS FOR CELL CULTURE | |
| SG11201806843UA (en) | Method for producing activated hepatocyte growth factor (hgf) | |
| MY183015A (en) | Solvent production using monophasic clostridia | |
| BR112021020501A2 (pt) | Meio de cultura celular para células eucarióticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/03/2016, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE A RPI 2744 DE 08/08/2023, QUANTO AO ITEM (54) TITULO. |